Zelira Therapeutics (G1G) Financial Statements
Zelira Therapeutics Financial Overview
Zelira Therapeutics's market cap is currently $3.73M. The company's EPS TTM is $-0.31; its P/E ratio is -1.56; Zelira Therapeutics is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 656.00 | $ 94.95K | $ 301.12K | $ 1.54M | $ 663.32K |
| Gross Profit | $ -802.95K | $ 10.28K | $ -3.22M | $ -5.72M | $ -39.16K |
| Operating Income | $ -3.95M | $ -5.94M | $ -7.41M | $ -13.41M | $ -9.65M |
| EBITDA | $ -4.05M | $ -36.44M | $ -6.79M | $ -13.06M | $ -9.41M |
| Net Income | $ -3.63M | $ -36.57M | $ -5.57M | $ -11.95M | $ -8.55M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 5.66K | $ 586.16K | $ 146.21K | $ 2.75M | $ 4.97M |
| Total Assets | $ 1.30M | $ 5.18M | $ 33.89M | $ 37.70M | $ 39.37M |
| Total Debt | $ 2.14M | $ 5.95M | $ 437.90K | $ 500.91K | $ 551.08K |
| Net Debt | $ 2.14M | $ 5.36M | $ 291.70K | $ -2.25M | $ -4.42M |
| Total Liabilities | $ 5.59M | $ 9.36M | $ 2.18M | $ 2.01M | $ 1.54M |
| Stockholders' Equity | $ -4.46M | $ -4.51M | $ 31.80M | $ 35.20M | $ 37.83M |
| Cash Flow | |||||
| Free Cash Flow | $ -4.91M | $ -4.39M | $ -7.25M | $ -9.43M | $ -8.62M |
| Operating Cash Flow | $ -4.91M | $ -4.39M | $ -7.25M | $ -9.43M | $ -8.62M |
| Investing Cash Flow | $ 1.15M | $ 919.74K | $ 2.83M | $ -207.78K | $ 1.38M |
| Financing Cash Flow | $ 3.19M | $ 3.92M | $ 1.77M | $ 7.10M | $ 10.53M |
Currency in AUD